undamentalytics Newsletter

Zanganeh Mahkam: insider trades

Chief executive, Officer, Director at 2 companies we cover. 18 open-market purchases and no sales not made under a pre-set plan, reported from February 22, 2017 to June 12, 2026.

Would copying Zanganeh Mahkam’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 12 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on February 23, 2017 into $1,724 by November 2, 2026, −16.6% a year. The copy held shares only 50% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $20,920, +7.9% a year (the S&P 500 held throughout made $37,245, +14.6% a year). Beta against the index was 0.36. Twelve months after each report, the average purchase was −33.6% against the S&P 500 (median −43.3%), and 25% beat it. Measured from the trade date, the insider’s own timing, the average was −24.4%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 20172019202120232025 $37.2k$20.9k$1.7k
Copying Zanganeh MahkamS&P 500, same days investedS&P 500, held throughout $10,000 copying Zanganeh Mahkam’s open-market purchases from February 23, 2017, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−16.6%
S&P 500, same days invested
+7.9% (held throughout +14.6%)
Time in shares
50%
Sharpe ratio (S&P 500)
−0.04 (0.70)
Biggest drop (S&P 500)
−95% (−34%)
Market sensitivity (beta)
0.36
Purchases copied
14

Trade by trade

Zanganeh Mahkam: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 14 +5.9% +0.6% 57% 5 0.56 0.61 No reliable evidence
Purchases, 6 months after the report 12 −0.6% −13.8% 42% 4 0.22 0.84 No reliable evidence
Purchases, 12 months after the report 12 −33.6% −43.3% 25% 4 −1.56 0.22 No reliable evidence
Purchases, 12 months after the trade 12 −24.4% −34.1% 25% 4 −1.05 0.37 No reliable evidence
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Pulse Biosciences, Inc. PLSE —90February 22, 2017June 25, 2020
Summit Therapeutics Inc. SMMT Co-Chief Executive Officer90May 14, 2021June 12, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 12, 2026June 12, 2026 SMMT Purchase $49,987,200 +22.5%not yetnot yet
June 4, 2026June 4, 2026 SMMT Purchase $1,460,000 +14.5%not yetnot yet
October 23, 2025October 21, 2025 SMMT Purchase $499,983 −20.5%−35.4%−32.1%
September 11, 2025September 10, 2025 SMMT Purchase $5,984,756 −10.1%−24.6%−18.8%
March 27, 2024March 26, 2024 SMMT Purchase $411,094 not yetnot yetnot yet
December 13, 2023December 12, 2023 SMMT Purchase $10,350 not yetnot yetnot yet
March 8, 2023March 8, 2023 SMMT Purchase $24,703,396 not yetnot yetnot yet
August 18, 2022August 16, 2022 SMMT Purchase $5,634,858 not yetnot yetnot yet
May 14, 2021May 12, 2021 SMMT Purchase $2,038,763 +1.0%−82.2%−79.5%
June 25, 2020June 23, 2020 PLSE Purchase $12,765 +0.3%+17.7%+32.5%
June 19, 2020June 17, 2020 PLSE Purchase $55,730 +1.9%+26.0%+42.7%
December 15, 2017December 13, 2017 PLSE Purchase $26,378 −40.5%−51.2%−49.7%
December 13, 2017December 11, 2017 PLSE Purchase $92,260 −44.5%−52.2%−49.0%
September 18, 2017September 14, 2017 PLSE Purchase $397,720 +54.2%−23.2%−24.0%
August 4, 2017August 2, 2017 PLSE Purchase $689,828 −10.6%−63.4%−64.5%
May 11, 2017May 9, 2017 PLSE Purchase $1,101,752 −17.3%−60.7%−36.2%
March 20, 2017March 17, 2017 PLSE Purchase $425,702 +39.9%−57.9%−57.0%
February 22, 2017February 15, 2017 PLSE Purchase $155,610 +91.6%+4.2%+43.0%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Zanganeh Mahkam traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.